Tesofensine
Tesofensine is a dopamine, serotonin, and noradrenaline (triple) reuptake inhibitor originally developed by NeuroSearch for the treatment of Alzheimer's disease and Parkinson's disease. Development of the compound for these neurological indications was unsuccessful but significant weight loss was reported during the clinical trials in Parkinson's disease.166 Hence, tesofensine is now being developed by NeuroSearch for the treatment of obesity and type 2 diabetes. In September 2007 NeuroSearch reported the outcome of a Phase IIb study with tesofensine for the treatment of obesity. Data from the study in 203 patients showed that 24-weeks’ treatment with tesofensine resulted in a dose-dependent weight loss of 6.5–12%. Tesofensine was reported to have a good safety profile and was well tolerated although an increased number of adverse events (e.g., increased heart rate and blood pressure) were observed in the highest dose groups of 0.5 mg and 1.0 mg. NeuroSearch167 stated that no clinically relevant cardiovascular adverse events or changes in either blood pressure or pulse were seen, according to FDA criteria